Stocks Health care BHST
NASDAQ · Health careBioharvest Sciences Inc. (BHST)
Bioharvest Sciences Inc. reported revenue of $34.5M in fiscal 2025, up 37.0% from a year earlier. It posted a net loss of $11.1M. In fiscal 2025 capital spending exceeded operating cash flow by $9.6M. At December 31, 2025 it held $23M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 31, 2026.
Key facts about Bioharvest Sciences Inc.
- Net worth
- Bioharvest Sciences Inc. has a market value (market cap) of $40.6M at the latest share price, and shareholders' equity of $25.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $34.5M (+37.0% year on year), with a net loss of $11.1M.
- Cash flow
- In fiscal 2025 operations used $7.2M of cash.
- Latest report
- The latest periodic report (annual report (Canadian issuer), 40-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Bioharvest Sciences Inc. does
Bioharvest Sciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BHST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $34.5M | -$11.1M | -$0.60 | -$9.6M |
| 2024 | $25.2M | -$12.9M | -$0.80 | -$9.5M |
| 2024 | $12.7M | -$12.6M | -$0.93 | -$10M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BHST ranks in Health care
Latest SEC filings
What Bioharvest Sciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026
- September 15, 2026
- September 15, 2026
- September 14, 2026
- September 3, 2026
- August 12, 2026
- August 11, 2026
- July 29, 2026
- July 28, 2026
- July 16, 2026
Insider trades
What the people running Bioharvest Sciences Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about BHST
What does Bioharvest Sciences Inc. do?
Bioharvest Sciences Inc. is a company in the Health care sector, listed on NASDAQ as BHST. Its shares trade on NASDAQ under the ticker BHST.
What is Bioharvest Sciences Inc.'s net worth?
Bioharvest Sciences Inc. has a market value (market cap) of $40.6M at the latest share price, and shareholders' equity of $25.4M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bioharvest Sciences Inc. profitable?
No. In fiscal 2025 it reported a net loss of $11.1M on revenue of $34.5M.
How much revenue does Bioharvest Sciences Inc. make?
In fiscal 2025 Bioharvest Sciences Inc. reported revenue of $34.5M. That is 37.0% more than a year earlier.
When did Bioharvest Sciences Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 2, 2026.
Similar companies
Compare BHST with
Follow BHST
Get an email when Bioharvest Sciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bioharvest Sciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.